Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Merger agrmnt [a]
Quarterly results
CC transcript
Inv. presentation
Director departure
Appointed director
AMICUS THERAPEUTICS, INC. (FOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
10/02/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
09/27/2023 8-K Quarterly results
08/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer"
08/15/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom"
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates",
"2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate..."
07/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/12/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "2 to a given date, such representation and warranty shall be true and correct in all material respects as of such specified date); and both immediately before and immediately after giving effect to this Agreement, no Default or Event of Default shall have occurred and be continuing. 4. Representations and Warranties. Each of the Borrower and Parent hereby represents and warrants to the Agent and the Lenders that no Default or Event of Default has occurred and is continuing as of the date hereof, the representations and warranties made by the Borrower and Parent contained in the Loan Documents are true and correct in all material respects as of the date hereof, except to the extent such representation or warranty expressly relates to an earlier date , the execution, delivery and performance..."
05/10/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics, Inc. Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Net product sales $ 86,270 $ 78,715 Cost of goods sold 6,942 7,582 Gross profit 79,328 71,133 Operating expenses: Research and development 41,499 81,517 Selling, general, and administrative 73,957 58,116 Changes in fair value of contingent consideration payable 251 Loss on impairment of assets — 6,616 Depreciation and amortization 1,257 1,411 Total operating expenses 116,964 146,472 Loss from operations Other income: Interest income 2,199 133 Interest expense Other income 1,902 Loss before income tax Income tax benefit 287 Net loss attributable to common stockholders $ $ Net loss attributable to common stockholders per common share — basic and diluted $ $ Weighted-average common share...",
"2 Forward-Looking Statements This presentation contains"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate ..."
04/26/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
03/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease"
03/01/2023 8-K Quarterly results
02/22/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023"
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook",
"2 Forward-Looking Statements Thispresentationcontains"forward-lookingstatements" withinthemeaningofthePrivateSecuritiesLitigationReformActof199 5relatingtopreclinicalandclinicaldevelopm entofourproductcandidates,thetimingandreportingofresultsf rompreclinicalstudiesandclinicaltrials,theprospe ctsandtimingofthepotentialregulatoryapp rovalofourproductcandida tes,commercializationplans,manufacturi ngandsupplyplans,financingplans,andtheprojectedrevenuesandcashpositionf ortheCompany.Th einclusionofforward-lookingstatementsshouldnotberegardedasarepresen tationbyusthatanyofourplanswillbeachieved. Anyoralloftheforward-lookingstatementsinthispressreleas emayturnouttobewrongandcanbeaffectedbyinaccurateass umptionswemightmakeorbyknownorunknownrisksanduncer tainties.Forexample,withrespecttostatements r..."
12/28/2022 8-K Quarterly results
12/16/2022 8-K Quarterly results
11/16/2022 8-K Quarterly results
11/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Provides EU Regulatory Update for AT-GAA",
"2 3 4 5"
11/07/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Equity Distribution Agreement, by and between Amicus Therapeutics, Inc. and Goldman Sachs & Co. LLC",
"Opinion of Troutman Pepper Hamilton Sanders LLP"
11/07/2022 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates",
"2 3 4 5"
10/28/2022 8-K Quarterly results
09/14/2022 8-K Investor presentation
Docs: "2 3 4 5"
08/04/2022 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2022 Financial Results",
"2Q22 Financial Results Conference Call & Webcast August 4, 2022 At the Forefront of Therapies for Rare Diseases"
08/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT"
06/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance",
"40th Annual J.P. Morgan Healthcare Conference January 12, 2022 At the Forefront of Therapies for Rare Diseases"
12/03/2021 8-K Quarterly results
11/18/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed to Provide a Differentiated Mechanism of Action and Potential Alternative Treatment Option for People Living with Late-onset Pompe Disease"
11/09/2021 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates",
"2 3 4 5"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy